Overview

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Status:
Recruiting
Trial end date:
2026-12-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
UCB Biopharma SRL